Harvesting Cells for Experimental Cancer Treatments

* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER: INCLUSION CRITERIA: * Patients must have a form of cancer currently being studied in the NCI-SB. * Patient is able to understand and willing to sign a written informed consent document. * Age greater than or equal to 18 years. * Clinical performance status of ECOG 0 or 1. * Serology * Seronegative for HIV antibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities). * Seronegative for hepatitis B surface antigen and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. * Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity. EXCLUSION CRITERIA: * Active systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system. * Patients who cannot give proper informed consent to the experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk. * Women of child-bearing potential who are pregnant because of the potentially danger…